NEW YORK — KDx Diagnostics has struck a US distribution deal for its urine-based URO17 bladder cancer test with EmeritusDx, the companies said on Monday.
URO17 uses the oncoprotein keratin 17 as a biomarker to detect new and recurrent bladder cancer. It received CE marking in mid-2020 and is available in the US as a laboratory-developed test.
Under the terms of the deal, Irvine, California-based EmeritusDx will offer URO17 testing to its network of urology practices across the US. Financial and other terms were not disclosed.
In May 2021, San Jose, California-based KDx partnered with Cardiff University, Cardiff and Vale University Health Board, and CellPath to evaluate the use of URO17 in patients with hematuria, as well as to develop a home sample collection program for the test.